Objective: Autofluorescence imaging (AFI) videobronchoscopy is a new endoscopic tool that improves visualization of neoplastic changes in the bronchial mucosa. The major aim of our study was to determine sensitivity and specificity of the technique in the assessment of tumor extent (margins). The secondary objective was to evaluate the possible effect of AFI on the change in therapeutic decisions of lung cancer treatment. Methods: In this prospective trial, we enrolled 104 patients in whom we performed 624 targeted biopsies, 3 from the pathologically altered mucosa (red-brownish or magenta colored) and 3 from randomly picked normal areas. We were using the Olympus BF-F260 videobronchoscope and EVIS LUCERA system. White light videobronchoscopy (WLB) preceded AFI examination and biopsy collection. All biopsy specimens were examined by a pathologist blinded to bronchoscopy findings, and where applicable surgically resected specimens were examined. Results: In 14.4% of the patients, AFI revealed a greater extent of the tumor than WLB, and in 11.5% that finding led to change in therapeutic decision (lesser or greater resection or avoidance of surgery). We found a significant correlation between tumor extent determined by AFI and changes in therapeutic decisions (P , 0.01). Sensitivity, specificity, positive predictive value and negative predictive value for AFI in the assessment of tumor extension were 93%, 92%, 92% and 93%, respectively. Corresponding results for WLB were 84%, 79%, 77% and 85%, respectively. Relative sensitivity of AFI is 1.11. Conclusions: Our results confirm that AFI videobronchoscopy significantly improves the assessment of central lung cancer extension and influences the therapeutic strategy. This technique has greater sensitivity and specificity, in assessment of tumor margins, than WLB alone.
INTRODUCTION
Autofluorescence bronchoscopy (AFB) is a diagnostic technique in interventional pulmonology usually used for detection of premalignant lesions and carcinoma in situ (CIS). The majority of AFB systems used during the last decade were fiberoptic tools. With recent development in technology, autofluorescence systems were added to videoendoscopy-the result was creation of AF videobronchoscopy. AFB found its place in diagnostic algorithms aimed at detection of precancerous lesions, CIS, radiographically occult lung cancer (ROLC) or early-stage lung cancer (ESLC) (1 -5) . However, AF videobronchoscopy has a greater potential. Recent studies have suggested that the autofluorescence imaging (AFI) system (Olympus Co., Tokyo, Japan) can be used in everyday practice for examination of tumor extent, post-operative examination after curative surgery or in longterm follow-up of surgically treated patients (6) . The secondgeneration AFI system is able to display both the images from conventional videoendoscope and autofluorescence on the same monitor. By adding the AF image to highresolution images of videobronchoscopy mode, diagnosis of premalignant and malignant tissue is simplified. Switching from conventional to autofluorescence mode by using a button is simple and reproducible. Malignant mucosa appears magenta colored, whereas normal mucosa is green.
The major objective of our study was to evaluate the specificity and sensitivity of AFI videobronchoscopy vs. white light videobronchoscopy (WLB), in the assessment of tumor extension in the major airways. The secondary objective was to investigate whether or not AFI videobronchoscopy can reveal greater extension of the tumor and, in that case, influence therapeutic decisions. In this trial, we did not use the AFI system for evaluation of premalignant lesions or synchronous tumors. We hypothesized that the addition of AFI to WLB will, in certain number of cases, reveal greater extension of the tumor in major airways, and that it might have an impact on therapeutic decisions for lung cancer treatment. Considering the fact that switching to AF mode on AFI videobronchoscopy system is simple, we were interested to evaluate how helpful it can be in routine diagnostic work-up of lung cancer. That is why in this study we enrolled only patients with high suspicion of central lung cancer, without suspected or known metastases.
PATIENTS AND METHODS
This was a prospective, non-randomized trial conducted at a university teaching clinic at the Institute for Pulmonary Diseases of Vojvodina in Serbia in the period from September 2007 to December 2008. The study was approved by the institutional review and ethics board. Partially, the study was performed as a part of the European Respiratory Society Short Term Training Fellowship; grant no. 627, at the Thoraxklinik, University of Heidelberg, Germany, under supervision of H.D.B. All of the patients who decided to participate in the study have been informed about the procedure, potential benefits and the risks, and all of them had signed an informed consent form. All of the patients screened for the enrollment were previously scheduled for routine bronchoscopy because of high clinical or radiological probability of lung cancer.
STUDY POPULATION
Inclusion criteria for enrollment in the study were: age over 18 years, chest radiology or computed tomographic (CT) scan highly suspicious for lung cancer, performance status ECOG 0 -2 and the absence of known or suspected lung cancer metastases. Exclusion criteria were: patients who did not want to participate in the study, ECOG 3, suspected or known lung cancer metastases, recent myocardial infarction, unresolved coagulopathies, unstable angina pectoris, chronic heart failure (NYHA 3), uncontrolled arrhythmia or hypertension and allergy to anesthetics. Prior to the enrollment in the study, all patients must have had chest X-ray, CT scan of the head, thorax and abdomen, spirometry and bodypletismography, blood gas analysis, complete blood count and blood biochemistry. One hundred and forty-seven patients were screened for the study, 104 of them met all the inclusion criteria, not having any exclusion. All eligible patients understood and signed the informed consent.
TECHNIQUE AND DESIGN
Bronchoscopic examination was performed in a dedicated respiratory endoscopy unit. Before the intervention, all of the patients were premedicated with midazolam and fentanyl. All of the routine vital parameters were monitored: noninvasive arterial blood pressure, oxygen saturation on pulse oximetry and ECG for cardiac rhythm. Bronchoscopic equipments used in the study were AF videobronchoscope BF-F260 (Olympus Co.), video processor unit EVIS LUCERA SPECTRUM (CV-260SL) (Olympus Co.) and xenon light source CLV-260SL (Olympus Co.). AF videobronchoscopy image was presented at a 19 in. LCD monitor OEV-191. EVIS LUCERA SPECTRUM video processor unit is based on black and white CCD chip technology, in which color separation is achieved through the use of an RGB color filter equipped with the light source unit. This system utilizes optical zoom with the capacity of 80-fold magnification of the picture. The AFI system utilizes highresolution imaging of the CCD chip at the distal end of the EVIS LUCERA SPECTRUM BF-F260 videobronchoscope. The examination of the tracheobronchial tree started with WLB. First, we examined trachea, then the side of the tracheobronchial tree that seemed to be healthy and afterwards the side of the tracheobronchial tree that was suspected to be pathologically changed. All the suspected changes in bronchial mucosa were first examined with the WLB and then we switched to the AFI mode and examined the pathologic areas more thoroughly. Abnormal areas visualized with WLB and AFI were recorded in digital format, and the picture was transmitted to the PC via intranet system connected to the processor unit and recorded in mpg, mpeg or avi format. Once the pathologic sites were identified, we performed targeted biopsies in order to obtain material for pathological examination. A dedicated lung pathologist
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Autofluorescence videobronchoscopy evaluated the biopsy specimens, blinded to bronchoscopic findings. In all patients, three biopsies were taken from places identified as pathologic either by WLB, AFI or both. Three control biopsies were taken from the places identified as normal. Pathologic areas were defined as red-brownish-or magenta-colored area, whereas the healthy area was green. Each targeted biopsy specimen was obtained by a separate dedicated forceps (usually FB-19C-1 or FB-15C-1). Biopsies were identified as positive if lung cancer tissue was identified. The overall number of biopsies taken from the abnormal places in the tracheobronchial tree was 312, and 312 biopsies were taken from the places that appeared normal under WLB and AFI, which are considered to be control. The biopsies were taken from the margins of the visualized pathologically changed mucosa; we did not use AFI for the diagnosis of gross tumor masses, as were evaluating its value in the assessment of tumor extent. Extension of the tumor was defined as wider if there was at least 1 cm greater extension observed by AFI than by WLB examination. In each patient, routine procedures were used for nodal staging and determination of the final stage of the disease. CT-guided transbronchial needle aspiration (TBNA) was performed in each patient, routinely sampling enlarged lymph nodes from stations 4, 7, 10 and 11. Enlarged lymph nodes were defined as nodes .1 cm in diameter assessed on CT scan. In some patients in whom surgical treatment was indicated, lymph node involvement was once again assessed by mediastinoscopy or video-assisted thoracotomy.
STATISTICAL ANALYSIS
Descriptive statistics were generated for all study variables, including mean and standard deviation for continuous variables and relative frequencies for categorical variables. Variables 'tumor extension' and 'role of AFI in the therapeutic decision' were measured by nominal dichotomous scale. One-sample Kolmogorov -Smirnov test was performed for testing the goodness of fit with the normal distribution. Pearson's x 2 test was used to compare the diagnostic sensitivity and specificity, and statistical significant differences between categorical variables, whereas Mann -Whitney test was used for testing the statistical significant differences between continuous variables. Spearman's analysis was performed to evaluate correlations between variables. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of AFI finding for the assessment of tumor extension were calculated. All probability values were calculated by assuming a two-tailed a value of 0.05 with confidence intervals (CIs) at the 95% level. All statistical analyses were performed with SPSS for Windows version 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
One hundred and four patients were included in the study, 85 male and 19 female. Average age of the patients was 56 + 12. Majority of the patients included in the study were current smokers 70.2%, former smokers 25% and nonsmokers only 4.8%. Patient characteristics are presented in Table 1 .
The most frequent type of lung cancer was squamous cell lung cancer; it was diagnosed in 77 patients (74%). In 20 patients (19.3%), histology confirmed adenocarcinoma, and in 7 patients (6.7%), we confirmed small cell lung cancer. A tumor .3 cm in longer axis assessed by CT scan was present in 46 patients (44.2%), tumor size between 2 and 3 cm was present in 41 patients (39.4%) and tumors ,2 cm in longer diameter were diagnosed in 17 patients (16.3%). Most frequent tumor localizations are presented in Table 2 .
In 15 patients (14.4%), AF videobronchoscopy revealed greater tumor extent than WLB alone. In these patients, tumor margins were .1 cm wider on AFI examination than on WLB. In 12 patients (11.5%), that finding influenced further therapeutic course, leading to greater resection level or avoidance of surgical treatment. In the three patients in whom the revealed extension was greater but did not influence therapeutic decision, the histological type of lung cancer was also squamous cell. We found a statistically significant correlation between tumor extent as assessed by AFI and influence on the therapeutic decision (P , 0.001). There is also a statistically significant correlation (P , 0.005) between tumor extent assessed by AFI and lung cancer type (squamous cell lung cancer). Patient and tumor characteristics as well as therapeutic decisions are stated in Table 3 .
In all patients in whom addition of AFI led to a change of therapeutic strategy, proper nodal staging was performed by CT-guided TBNA. Definite nodal stage was evaluated during mediastinoscopy and video-assisted thoracotomy. The nodal stage did not influence therapeutic decision in those patients. 
DISCUSSION
One of the most important findings of this study is the capability of AFI to reveal greater extent of centrally located lung cancer and its capacity to influence and change therapeutic decision. Our study suggests that AFB could be used in the assessment of lung cancer extension in everyday routine diagnostic bronchoscopy. We found a better sensitivity and specificity of AFI over WLB; the relative sensitivity ratio of 1.1 confirms that claim. This study might induce further trials on AFB in addition to ESLC. It is established that autofluorescence is the preferable technique in the detection of ROLC and pre-invasive malignant lesions of 
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Autofluorescence videobronchoscopy bronchial mucosa. However, we believe that new technologies should be utilized in everyday practice, whenever possible and if they prove to be of additional value. The major reason for better specificity in our study is the fact that we evaluated cases highly suspicious for invasive lung cancer. The largest number of studies evaluated pre-invasive lesions, CIS or ROLC. Our previously published pilot trial was a cornerstone for the present study, which is confirming our preliminary results (6) . The largest European multicentre trial, conducted by Häussinger et al. (3), confirmed that the biopsy-based sensitivity of WLB alone and WLB þ AF for detection of precancerous lesions and CIS was 57.9% vs. 82.3%, respectively. The corresponding specificity was 62.1% compared with 58.4%. The result of this trial showed that combination of WLB þ AFB was significantly superior in detection of precancerous lesions. Their findings did not support the general use of AFB as a screening tool in lung cancer. Results of this trial suggest that AFB might be useful in certain risk groups. That study was performed on 1173 patients using D-light system (Karl Storz, Tuttlingen, Germany) and evaluated pre-invasive lesions. That might be the reason for lower sensitivity and specificity than reported in our study, in which we evaluated the extent of highly suspected invasive lesions. The European Respiratory Society/American Thoracic Society statement on interventional pulmonology suggests the use of autofluorescence in location of malignant and premalignant lesions that may not be identifiable with conventional bronchoscopy (5). In our previous publication on AFI system, the diagnostic value the relative sensitivity of AFI over WLB was 1.41. Sensitivity, specificity, PPV and NPV of AFI are comparable in both studies: 90%, 85%, 78% and 94%, respectively. In a smaller number of patients, we found a significant influence of AFI on tumor extent and therapeutic decision. In the study published by Chiyo et al. (7), AFI system had a better sensitivity (80%) and specificity (83%) than LIFE system (Xillix Technologies, Richmond, Canada). The authors investigated the value of AFI in distinguishing pre-invasive and malignant lesions from bronchitis or hyperplasia. In our study, AFI showed a better sensitivity (93%) and specificity (92%) for evaluation of the extent of malignant lesions. In the study published by Ueno et al. (8) , the sensitivity of AFI and WLB for detection of severe dysplasia was 94.7% and 73%, respectively. These results are consistent with ours; we found a sensitivity of 93% for AFI and 84% for WLB. The higher sensitivity of WLB in our study is probably a result of the fact that we have evaluated the margins of invasive lesions. Several studies investigated the effectiveness of AFB in detection of synchronous lesions and confirmed the superiority of AF over WLB. van Rens et al. (9) concluded that the LIFE system should be used in the work-up of patients with primary lung cancer, whereas Pierard et al. (10) concluded that AFB may be a useful adjunct in the pre-treatment evaluation of patients with CIS or ROLC. Very similar conclusions result from our study, too. In our study, in several cases, we found moderate dysplasia on the margins of the tumor. However, these lesions were not qualified to be designated as malignant and their presence did not influence the therapeutic decision. In 10 patients, we found dysplasia on the margins of malignant tumor. Seven of the patients in IIIB stage requiring chemo-radiotherapy, three were in IIIA and they received neoadjuvant therapy. The occasional findings of precancerous lesions did not influence the results of the study. In one patient, we found synchronous CIS, and that lesion was treated with argon plasma coagulation. However, it was the patient in IIIB stage who required chemotherapy and radiotherapy, so that finding did not influence the results of the study. We found AFI superior for evaluation of tumor extent and concluded that it could be added to the routine work-up of patients with suspected lung cancer. A clinical study similar to ours was performed in 2004 by Tsunezuka et al. (11) . The authors evaluated the influence of the LIFE system on selection of the surgical procedure in patients with known lung cancer. In their study, LIFE revealed larger abnormal areas of lung cancer compared with WLB in 58.3% of the patients. In our study, AFI revealed greater extension of cancer in 14.4% of the patients. Among seven patients in Tsunezuka's study in whom LIFE proved greater extension of the tumor, the course of the therapy was changed in four. In our study group, therapeutic decision was changed in 12 of 15 patients in whom AFI revealed greater tumor extension. The difference in the number of patients in whom AF altered therapy could be a result of differences in AF systems used for detection of lung cancer. In our study, we included a larger number of patients for evaluation. Weigel et al. (12) reported that AFB might have a place in bronchoscopic surveillance after surgical resection for non-small-cell lung caner. The authors used Jpn J Clin Oncol 2010;40(2) 143 the LIFE system to identify second lung primaries in patients who had a previous resection of a non-small-cell lung cancer. The addition of LIFE AFB increased the sensitivity of screening from 25% to 75%. That yielded a relative sensitivity of 300% and an NPV of 0.97. Twenty-five patients were enrolled in this study with a total number of 31 bronchoscopies. In our study, AFI increased sensitivity from 84% to 93% for evaluation of malignant lesions, but we performed 104 bronchoscopies in 104 patients. Ikeda et al. (13) evaluated the performance of AFB (LIFE system) based on analysis of thin sections of the bronchi of resected lung and compared it with pre-operative AFB results. There were 30 patients enrolled in this study. The sensitivity of WLB for cancer was 90% and for dysplasia 31%. The respective figures for AFB were 97% for cancer and 50% for dysplasia. The specificity of WLB and AFB was 88% and 84%, respectively. The authors concluded that AF examination showed a better sensitivity for cancerous/precancerous lesions, and that the evaluation of the extent of cancer invasion was accurate. In our study, the sensitivity and specificity of AFI were 93% and 92%, the results quite comparable to those of Ikeda et al. In 2005, Lam et al. (14) published a study with the aim to evaluate the role of AFB in the routine work-up of lung cancer. Two groups of patients were examined, one with sputum atypia and the other with suspicious cells in sputum: overall sensitivity of AFB was 91.7%, whereas WLB had a sensitivity of 58.3%, and the corresponding specificities were 26.4% and 50%, respectively. The authors used the SAFE 1000 system (Pentax, Tokyo, Japan). In our study, the sensitivity of AFI system was 93%, but the specificity was much higher-92%. The different technology of AFB and the larger number of patients might be a reason for differences in the results. In Lam et al's study, the majority of patients had precancerous lesions, whereas in our study, most of the patients were diagnosed with invasive lung cancer. A similar patient population to ours was evaluated by Hanibuchi et al. (15) . The majority of the patients enrolled in their study had malignant disease (77.2%). Hanibuchi et al. found the sensitivity of AFB (SAFE 1000, Pentax) to be higher than that in our study 96.8%, whereas the specificity was 56.1%, PPV 52.1% and NPV 97.2%. The results of our study are in consistency, with slightly higher specificity and PPV. Chhajed et al. (16) evaluated the diagnostic yield of flexible videobronchoscopy (FVB) and AFB (LIFE system) in patients at high risk for lung cancer. The results of their study showed that the sensitivity of FVB and LIFE was 72% and 96%, respectively, and the relative sensitivity of LIFE over FVB was 1.33, confirming better diagnostic yield of LIFE. Relative sensitivity of AFI over WLB videobronchoscopy in our study was 1.1, whereas the sensitivity of AFI in our study was 93%. In 2007, Lee et al. (17) published a study that evaluated SAFE 3000 dual digital video autofluorescence imaging for early detection of lung cancer. They concluded that the system achieves good sensitivity and specificity and facilitates targeted biopsies. The same results were observed in our study. A respectable number of studies confirmed the importance and value of AFB in detection of ESLC and ROLC (18 -22) . Some of these studies were not performed by videobronchoscopy, and that is the reason why the results may vary from study to study. However, AF videobronchoscopy may offer different diagnostic opportunities and that is why it should be further investigated in everyday diagnostic bronchoscopy.
CONCLUSION
The AFI videobronchoscopy system (Olympus Co.) yields significantly higher sensitivity and specificity for the assessment of lung cancer extent than WLB videobronchoscopy alone. It was shown to be able to influence therapeutic options for lung cancer treatment in a significant number of patients. Results of our study suggest that AFI is most efficient in squamous cell lung cancer. The addition of this technology to standard bronchoscopic examination during lung cancer staging proved to be justified. Further studies of AF videobronchoscopy should be widened on examination of its use in everyday diagnostics, especially in high-risk population.
